1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Equipment & Services
Balaxi Pharmaceuticals Limited

Balaxi Pharmaceuticals Limited

BALAXI.NS
Balaxi Pharmaceuticals LimitedIN flagNational Stock Exchange of India
24.00
INR
+0.15
- -
267.20MMarket Cap
Balaxi Pharmaceuticals Limited
BALAXI.NS
(National Stock Exchange of India)

Recent

price

24.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
0.08
0.03
- -
- -
8.94
12.13
46.27
55.88
67.06
46.88
52.98
- -
49.84
Revenue per Share
0.07
-0.05
-0.11
-0.51
1.29
1.62
7.63
9.53
9.16
-0.46
4.54
- -
0.26
Basic EPS, GAAP
0.14
-0.03
-0.09
-0.45
-1
-3.78
-0.51
1.47
-1.32
0.64
-10.28
- -
- -
Free Cash Flow per Basic Share
0.05
0.07
- -
- -
- -
- -
- -
- -
0.1
- -
- -
- -
- -
Dividend per Share
0.02
1.54
1.42
0.92
2.21
4.37
10.74
20.37
30.56
28.5
31.6
- -
2.04
Book Value per Share
0.02
1.64
1.53
1.02
2.32
7.38
12.74
17.81
31.25
33.9
37
- -
39.92
Tangible Book Value per Share
15
15
15
15
15
38
50
50
50
51
55
- -
54
Basic Weighted Avg Shares
1
- -
- -
- -
136
456
2,313
2,794
3,364
2,413
2,926
2,702
2,702
Sales/Revenue/Turnover
35.04
-99.69
- -
- -
12.02
18.07
18.34
18.01
16.54
18.98
12.07
2.36
2.36
Operating Margin (%)
- -
- -
- -
- -
- -
- -
3
5
18
21
19
22
22
Depreciation Expense
1
-1
-2
-8
20
61
381
477
460
-24
251
14
14
Net Income, GAAP
30.44
- -
- -
- -
19.41
30.59
13.97
12.59
19.25
218.44
12.55
73.23
73.23
Effective Tax Rate (%)
82.71
-169.17
- -
- -
14.46
13.38
16.49
17.06
13.66
-0.99
8.57
0.52
0.52
Profit Margin (%)
- -
25
23
15
32
266
591
777
1,404
1,560
1,882
1,893
1,893
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
26
17
230
242
242
LT Debt
- -
25
23
16
35
277
650
1,132
1,829
2,014
2,317
2,491
2,491
Total Equity
- -
- -
- -
- -
47.31
31.25
68.03
44.26
27.21
-25.23
11.98
0.57
0.57
Return on Invested Capital (%)
- -
- -
- -
- -
82.79
61.64
103.41
58.68
34.08
-2.63
14.03
1.66
1.66
Return on Capital (%)
- -
-6.79
-7.75
-43.34
82.79
61.64
108.77
61.28
36.03
-1.59
15.61
1.53
1.53
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
333
- -
334
LT Borrowings
214
- -
224
LT Finance Leases
18
- -
19
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
55
- -
55
Market Capitalization
2,410
1,454
849

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
2,384
- -
2,514
Cash, Cash Equivalents & STI
388
- -
146
Accounts Receivable, Net
1,092
- -
1,361
Inventories
781
- -
835
Total Current Liabilities
602
- -
622
Payables & Accruals
- -
- -
- -
ST Debt
333
- -
334
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
107.71%
33.69%
7.48%
Free Cash Flow
-102.33%
-513.4%
-16.59%
Net Income, GAAP
-48.98%
-265.68%
-94.35%
Sales/Revenue/Turnover
- -
5.3%
-7.65%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
660
547
608
598
2,413
2025
656
774
733
763
2,926
2026
707
562
725
707
2,702

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-8.1
2.82
2.66
- -
-0.46
2025
1.17
0.84
0.97
1.56
4.54
2026
0.05
0.04
0.06
0.11
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Landauer Inc. (LDR)
Cerner Corporation (0R00.L)
Cotiviti Holdings, Inc. (COTV)
Advisory Board Co. (The) (ABCO)
Hologic Inc (HO1.DE)
LifePoint Health, Inc. (LPNT)
Business
Balaxi Pharmaceuticals Limited is a pharmaceutical company primarily engaged in the manufacturing, marketing, and distribution of pharmaceutical formulations and bulk drugs. Its product portfolio includes tablets, capsules, injectables, ointments, and syrups across various therapeutic segments such as anti-infectives, analgesics, anti-inflammatory, cardiovascular, and gastrointestinal drugs. The company operates manufacturing facilities complying with regulatory standards and serves markets primarily in India, with an expanding footprint in select international markets. Founded in 1988 and headquartered in Ahmedabad, Gujarat, Balaxi Pharmaceuticals also focuses on research and development for new drug formulations and improving existing ones. In the past 1-2 years, Balaxi Pharmaceuticals has undertaken strategic initiatives including expansions in its manufacturing capabilities and the launch of new product lines to enhance its therapeutic offerings. It has formed partnerships to strengthen its distribution network and improve market penetration. Balaxi has also invested in upgrading technology for better compliance with international quality standards, supporting its ambition to grow in export markets. There have been no recent changes in company name or major restructuring reported. The company continues to focus on innovation, market expansion, and operational efficiency as part of its growth strategy in the pharmaceutical industry. Balaxi operates primarily in the pharmaceutical industry, targeting healthcare providers, hospitals, and retail pharmacies. Its business segments cover generic pharmaceuticals, contract manufacturing, and formulation development. The company is recognized for maintaining compliance with health regulations and pharmaceutical best practices, aiming to deliver quality medicines across various therapeutic areas. Balaxi Pharmaceuticals Limited remains an important player in India’s pharmaceutical sector with evolving plans to broaden its reach and product base. This description incorporates details of Balaxi Pharmaceuticals' core products and services as well as its recent strategic developments and operational focus. It reflects the company’s ongoing commitment to pharmaceutical manufacturing excellence and market growth in India and beyond.